Patent · US Active

Sin Nombre virus full-length M segment-based DNA vaccines

US11155834B2 · kind B2 · utility

0Cited by

10References

19Claims

0Family size

Assignee

The Government of the United States, as represented by the Secretary of the Army · US

Inventor

Jay Hooper · New Market, US

Key dates

Filing date	Aug 28, 2019
Grant date	Oct 26, 2021
Priority date	—
Expiry date	Aug 28, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/12151
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.